CABALETTA BIO, INC. Proceeds from Common Stock Issued
CABALETTA BIO, INC. (CABA) reported Proceeds from Common Stock Issued of $13.19 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfCommonStock · last filed 2026-08-13
- CABALETTA BIO, INC. proceeds from issuance of common stock for the quarter ending 2026-06-30 was $6.25M.
- CABALETTA BIO, INC. proceeds from issuance of common stock for the quarter ending 2026-03-31 was $6.94M.
- CABALETTA BIO, INC. proceeds from issuance of common stock for the quarter ending 2025-12-31 was $0.00.
- CABALETTA BIO, INC. proceeds from issuance of common stock for the quarter ending 2025-09-30 was $93.56M.
- CABALETTA BIO, INC. proceeds from issuance of common stock for fiscal 2025 was $93.56M.
- CABALETTA BIO, INC. proceeds from issuance of common stock for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- CABALETTA BIO, INC. proceeds from issuance of common stock for fiscal 2023 was $185.20M, a 463.70% increase from fiscal 2022.
- CABALETTA BIO, INC. proceeds from issuance of common stock for fiscal 2022 was $32.85M, a 31.91% decline from fiscal 2021.
| Period end | Proceeds from Issuance of Common Stock 3 month | Proceeds from Issuance of Common Stock 6 month | Proceeds from Issuance of Common Stock 6 month as first filed | Proceeds from Issuance of Common Stock 9 month | Proceeds from Issuance of Common Stock 9 month as first filed | Proceeds from Issuance of Common Stock 12 month | Proceeds from Issuance of Common Stock 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $6.25M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $13.19M 10-Q · filed 2026-08-13 | $13.19M derived: sum of 3 quarters · filed 2026-08-13 | $106.75M derived: sum of 4 quarters · filed 2026-08-13 | |||
| 2026-03-31 | $6.94M 10-Q · filed 2026-05-14 | $6.94M derived: sum of 2 quarters · filed 2026-05-14 | $100.50M derived: sum of 3 quarters · filed 2026-05-14 | $100.50M derived: sum of 4 quarters · filed 2026-08-13 | |||
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $93.56M derived: sum of 2 quarters · filed 2026-03-23 | $93.56M derived: sum of 3 quarters · filed 2026-08-13 | $93.56M 10-K · filed 2026-03-23 | |||
| 2025-09-30 | $93.56M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $93.56M derived: sum of 2 quarters · filed 2026-08-13 | $93.56M 10-Q · filed 2025-11-10 | $93.56M derived: sum of 4 quarters · filed 2026-08-13 | |||
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $0.00 10-Q · filed 2026-08-13 | $93.58M 10-Q · filed 2025-08-07 | $0.00 derived: sum of 3 quarters · filed 2026-08-13 | $0.00 derived: sum of 4 quarters · filed 2026-08-13 | ||
| 2025-03-31 | $0.00 10-Q · filed 2026-05-14 | $0.00 derived: sum of 2 quarters · filed 2026-05-14 | $0.00 derived: sum of 3 quarters · filed 2026-05-14 | -$5.75M derived: sum of 4 quarters · filed 2026-05-14 | |||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $0.00 derived: sum of 2 quarters · filed 2026-03-23 | -$5.75M derived: sum of 3 quarters · filed 2026-03-23 | $0.00 10-K · filed 2026-03-23 | $10.88M 10-K · filed 2025-03-31 | ||
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | -$5.75M derived: sum of 2 quarters · filed 2025-11-10 | $0.00 10-Q · filed 2025-11-10 | $5.75M 10-Q · filed 2024-11-14 | $91.74M derived: sum of 4 quarters · filed 2025-11-10 | ||
| 2024-06-30 | -$5.75M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $0.00 10-Q · filed 2025-08-07 | $5.75M 10-Q · filed 2024-08-08 | $91.74M derived: sum of 3 quarters · filed 2025-08-07 | $91.60M derived: sum of 4 quarters · filed 2025-08-07 | ||
| 2024-03-31 | $5.75M 10-Q · filed 2025-05-15 | $97.48M derived: sum of 2 quarters · filed 2025-05-15 | $97.34M derived: sum of 3 quarters · filed 2025-05-15 | $191.18M derived: sum of 4 quarters · filed 2025-05-15 | |||
| 2023-12-31 | $91.74M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $91.60M derived: sum of 2 quarters · filed 2025-03-31 | $185.43M derived: sum of 3 quarters · filed 2025-03-31 | $185.20M 10-K · filed 2025-03-31 | |||
| 2023-09-30 | -$141.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $93.69M derived: sum of 2 quarters · filed 2024-11-14 | $93.46M 10-Q · filed 2024-11-14 | $126.32M derived: sum of 4 quarters · filed 2024-11-14 | |||
| 2023-06-30 | $93.84M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $93.60M 10-Q · filed 2024-08-08 | $126.46M derived: sum of 3 quarters · filed 2024-08-08 | $126.46M derived: sum of 4 quarters · filed 2024-08-08 | |||
| 2023-03-31 | -$232.00K 10-Q · filed 2024-05-15 | $32.62M derived: sum of 2 quarters · filed 2024-05-15 | $32.62M derived: sum of 3 quarters · filed 2024-05-15 | $32.62M derived: sum of 4 quarters · filed 2024-05-15 | |||
| 2022-12-31 | $32.85M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | $32.85M derived: sum of 2 quarters · filed 2024-03-21 | $32.85M derived: sum of 3 quarters · filed 2024-03-21 | $32.85M 10-K · filed 2024-03-21 | |||
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $0.00 derived: sum of 2 quarters · filed 2023-11-09 | $0.00 10-Q · filed 2023-11-09 | $13.54M derived: sum of 4 quarters · filed 2023-11-09 | |||
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $0.00 10-Q · filed 2023-08-10 | $13.54M derived: sum of 3 quarters · filed 2023-08-10 | $38.42M derived: sum of 4 quarters · filed 2023-08-10 | |||
| 2022-03-31 | $0.00 10-Q · filed 2023-05-11 | $13.54M derived: sum of 2 quarters · filed 2023-05-11 | $38.42M derived: sum of 3 quarters · filed 2023-05-11 | $46.09M derived: sum of 4 quarters · filed 2023-05-11 | |||
| 2021-12-31 | $13.54M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | $38.42M derived: sum of 2 quarters · filed 2023-03-16 | $46.09M derived: sum of 3 quarters · filed 2023-03-16 | $48.25M 10-K · filed 2023-03-16 | |||
| 2021-09-30 | $24.88M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $32.55M derived: sum of 2 quarters · filed 2022-11-10 | $34.71M 10-Q · filed 2022-11-10 | $34.71M derived: sum of 4 quarters · filed 2022-11-10 | |||
| 2021-06-30 | $7.67M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $9.83M 10-Q · filed 2022-08-11 | $9.83M derived: sum of 3 quarters · filed 2022-08-11 | $9.83M derived: sum of 4 quarters · filed 2022-08-11 | |||
| 2021-03-31 | $2.17M 10-Q · filed 2022-05-12 | $2.16M derived: sum of 2 quarters · filed 2022-05-12 | $2.16M derived: sum of 3 quarters · filed 2022-05-12 | $2.02M derived: sum of 4 quarters · filed 2022-05-12 | |||
| 2020-12-31 | -$1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | -$1.00K derived: sum of 2 quarters · filed 2022-03-17 | -$148.00K derived: sum of 3 quarters · filed 2022-03-17 | -$192.00K 10-K · filed 2022-03-17 | |||
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-01 | -$147.00K derived: sum of 2 quarters · filed 2021-11-01 | -$191.00K 10-Q · filed 2021-11-01 | $73.12M derived: sum of 4 quarters · filed 2021-11-01 | |||
| 2020-06-30 | -$147.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | -$191.00K 10-Q · filed 2021-08-05 | $73.12M derived: sum of 3 quarters · filed 2021-08-05 | ||||
| 2020-03-31 | -$44.00K 10-Q · filed 2021-05-03 | $73.27M derived: sum of 2 quarters · filed 2021-05-03 | |||||
| 2019-12-31 | $73.31M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-16 | $71.21M 10-K · filed 2021-03-16 | |||||
| 2019-09-30 | -$2.10M 10-Q · filed 2020-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |